Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids

Gregory C. Shearer, Kamil Borkowski, Susan L. Puumala, William S. Harris, Theresa L. Pedersen, John W. Newman

Research output: Research - peer-reviewArticle

Abstract

Metabolic syndrome (MetSyn) is characterized by chronic inflammation which mediates the associated high risk for cardiovascular and other diseases. Oxylipins are a superclass of lipid mediators with potent bioactivities in inflammation, vascular biology, and more. While their role as locally produced agents is appreciated, most oxylipins in plasma are found in lipoproteins suggesting defective regulation of inflammation could be mediated by the elevated VLDL and low HDL levels characteristic of MetSyn. Our objective was to compare the oxylipin composition of VLDL, LDL, and HDL in 14 optimally healthy individuals and 31 MetSyn patients, and then to determine the effects of treating MetSyn subjects with 4 g/day of prescription omega-3 fatty acids (P-OM3) on lipoprotein oxylipin profiles. We compared oxylipin compositions of healthy (14) and MetSyn (31) subjects followed by randomization and assignment to 4 g/d P-OM3 for 16 weeks using LC/MS/MS. Compared to healthy subjects, MetSyn is characterized by abnormalities of (1) pro-inflammatory, arachidonate-derived oxylipins from the lipoxygenase pathway in HDL; and (2) oxylipins mostly not derived from arachidonate in VLDL. P-OM3 treatment corrected many components of these abnormalities, reducing the burden of inflammatory mediators within peripherally circulating lipoproteins that could interfere with, or enhance, local effectors of inflammatory stress. We conclude that MetSyn is associated with a disruption of lipoprotein oxylipin patterns consistent with greater inflammatory stress, and the partial correction of these dysoxylipinemias by treatment with omega-3 fatty acids could explain some of their beneficial effects.

LanguageEnglish (US)
Pages1-10
Number of pages10
JournalProstaglandins Leukotrienes and Essential Fatty Acids
Volume128
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Oxylipins
Omega-3 Fatty Acids
Lipoproteins
Inflammation
Therapeutics
Chemical analysis
HDL2 Lipoprotein
Lipoxygenase
Random Allocation
Prescriptions
Blood Vessels
Healthy Volunteers
Cardiovascular Diseases
Lipids
low density lipoprotein inhibitor
Bioactivity
Plasmas
oxidized low density lipoprotein

Keywords

  • DHA
  • EPA
  • Epoxides
  • HDL
  • LDL
  • Lipid mediators
  • Lipoproteins
  • Metabolic syndrome
  • Omega-3 acid ethyl esters
  • Omega-3 fatty acids
  • Oxylipins
  • VLDL

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology

Cite this

Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids. / Shearer, Gregory C.; Borkowski, Kamil; Puumala, Susan L.; Harris, William S.; Pedersen, Theresa L.; Newman, John W.

In: Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 128, 01.01.2018, p. 1-10.

Research output: Research - peer-reviewArticle

Shearer, Gregory C. ; Borkowski, Kamil ; Puumala, Susan L. ; Harris, William S. ; Pedersen, Theresa L. ; Newman, John W./ Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids. In: Prostaglandins Leukotrienes and Essential Fatty Acids. 2018 ; Vol. 128. pp. 1-10
@article{37a279a0d1624c06a3ec1d71edcd5ddc,
title = "Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids",
abstract = "Metabolic syndrome (MetSyn) is characterized by chronic inflammation which mediates the associated high risk for cardiovascular and other diseases. Oxylipins are a superclass of lipid mediators with potent bioactivities in inflammation, vascular biology, and more. While their role as locally produced agents is appreciated, most oxylipins in plasma are found in lipoproteins suggesting defective regulation of inflammation could be mediated by the elevated VLDL and low HDL levels characteristic of MetSyn. Our objective was to compare the oxylipin composition of VLDL, LDL, and HDL in 14 optimally healthy individuals and 31 MetSyn patients, and then to determine the effects of treating MetSyn subjects with 4 g/day of prescription omega-3 fatty acids (P-OM3) on lipoprotein oxylipin profiles. We compared oxylipin compositions of healthy (14) and MetSyn (31) subjects followed by randomization and assignment to 4 g/d P-OM3 for 16 weeks using LC/MS/MS. Compared to healthy subjects, MetSyn is characterized by abnormalities of (1) pro-inflammatory, arachidonate-derived oxylipins from the lipoxygenase pathway in HDL; and (2) oxylipins mostly not derived from arachidonate in VLDL. P-OM3 treatment corrected many components of these abnormalities, reducing the burden of inflammatory mediators within peripherally circulating lipoproteins that could interfere with, or enhance, local effectors of inflammatory stress. We conclude that MetSyn is associated with a disruption of lipoprotein oxylipin patterns consistent with greater inflammatory stress, and the partial correction of these dysoxylipinemias by treatment with omega-3 fatty acids could explain some of their beneficial effects.",
keywords = "DHA, EPA, Epoxides, HDL, LDL, Lipid mediators, Lipoproteins, Metabolic syndrome, Omega-3 acid ethyl esters, Omega-3 fatty acids, Oxylipins, VLDL",
author = "Shearer, {Gregory C.} and Kamil Borkowski and Puumala, {Susan L.} and Harris, {William S.} and Pedersen, {Theresa L.} and Newman, {John W.}",
year = "2018",
month = "1",
doi = "10.1016/j.plefa.2017.10.006",
volume = "128",
pages = "1--10",
journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",
issn = "0952-3278",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids

AU - Shearer,Gregory C.

AU - Borkowski,Kamil

AU - Puumala,Susan L.

AU - Harris,William S.

AU - Pedersen,Theresa L.

AU - Newman,John W.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Metabolic syndrome (MetSyn) is characterized by chronic inflammation which mediates the associated high risk for cardiovascular and other diseases. Oxylipins are a superclass of lipid mediators with potent bioactivities in inflammation, vascular biology, and more. While their role as locally produced agents is appreciated, most oxylipins in plasma are found in lipoproteins suggesting defective regulation of inflammation could be mediated by the elevated VLDL and low HDL levels characteristic of MetSyn. Our objective was to compare the oxylipin composition of VLDL, LDL, and HDL in 14 optimally healthy individuals and 31 MetSyn patients, and then to determine the effects of treating MetSyn subjects with 4 g/day of prescription omega-3 fatty acids (P-OM3) on lipoprotein oxylipin profiles. We compared oxylipin compositions of healthy (14) and MetSyn (31) subjects followed by randomization and assignment to 4 g/d P-OM3 for 16 weeks using LC/MS/MS. Compared to healthy subjects, MetSyn is characterized by abnormalities of (1) pro-inflammatory, arachidonate-derived oxylipins from the lipoxygenase pathway in HDL; and (2) oxylipins mostly not derived from arachidonate in VLDL. P-OM3 treatment corrected many components of these abnormalities, reducing the burden of inflammatory mediators within peripherally circulating lipoproteins that could interfere with, or enhance, local effectors of inflammatory stress. We conclude that MetSyn is associated with a disruption of lipoprotein oxylipin patterns consistent with greater inflammatory stress, and the partial correction of these dysoxylipinemias by treatment with omega-3 fatty acids could explain some of their beneficial effects.

AB - Metabolic syndrome (MetSyn) is characterized by chronic inflammation which mediates the associated high risk for cardiovascular and other diseases. Oxylipins are a superclass of lipid mediators with potent bioactivities in inflammation, vascular biology, and more. While their role as locally produced agents is appreciated, most oxylipins in plasma are found in lipoproteins suggesting defective regulation of inflammation could be mediated by the elevated VLDL and low HDL levels characteristic of MetSyn. Our objective was to compare the oxylipin composition of VLDL, LDL, and HDL in 14 optimally healthy individuals and 31 MetSyn patients, and then to determine the effects of treating MetSyn subjects with 4 g/day of prescription omega-3 fatty acids (P-OM3) on lipoprotein oxylipin profiles. We compared oxylipin compositions of healthy (14) and MetSyn (31) subjects followed by randomization and assignment to 4 g/d P-OM3 for 16 weeks using LC/MS/MS. Compared to healthy subjects, MetSyn is characterized by abnormalities of (1) pro-inflammatory, arachidonate-derived oxylipins from the lipoxygenase pathway in HDL; and (2) oxylipins mostly not derived from arachidonate in VLDL. P-OM3 treatment corrected many components of these abnormalities, reducing the burden of inflammatory mediators within peripherally circulating lipoproteins that could interfere with, or enhance, local effectors of inflammatory stress. We conclude that MetSyn is associated with a disruption of lipoprotein oxylipin patterns consistent with greater inflammatory stress, and the partial correction of these dysoxylipinemias by treatment with omega-3 fatty acids could explain some of their beneficial effects.

KW - DHA

KW - EPA

KW - Epoxides

KW - HDL

KW - LDL

KW - Lipid mediators

KW - Lipoproteins

KW - Metabolic syndrome

KW - Omega-3 acid ethyl esters

KW - Omega-3 fatty acids

KW - Oxylipins

KW - VLDL

UR - http://www.scopus.com/inward/record.url?scp=85033409250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033409250&partnerID=8YFLogxK

U2 - 10.1016/j.plefa.2017.10.006

DO - 10.1016/j.plefa.2017.10.006

M3 - Article

VL - 128

SP - 1

EP - 10

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

T2 - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

SN - 0952-3278

ER -